"KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma"@en . . . . . "Demlov\u00E1, Regina" . "Val\u00EDk, Dalibor" . . "Dubsk\u00E1, Lenka" . "\u010Casopis l\u00E9ka\u0159\u016F \u010Desk\u00FDch" . . . . "Vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS jako sou\u010D\u00E1st algoritmu l\u00E9\u010Dby metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu" . "Targeted therapy has become an integral part of treatment procedures of malignant tumors. Colorectal carcinomas are frequently targeted with monoclonal anti-EGFR antibodies (cetuximab and panitumumab). Activating somatic mutations in codons 12 and 13 of the exon 2 of KRAS gene are considered negative predictive factors of response to anti-EGFR therapy in patients with metastatic colorectal cancer. In the Czech Republic, evaluation of mutational status of KRAS gene is performed in several referral laboratories. In 2009, these laboratories performed 2580 tests of the KRAS mutational status \u2013 out of these, 60.2% cases reported non-mutated, wild-type KRAS. In one of the referral laboratories, we demonstrate the logistics of KRAS testing procedure. Stratification of patients with metastatic colorectal tumors based on their KRAS mutational status has evolved to a standard procedure. Laboratories performing these methods shall therefore adhere to the recommendations of the professional and accredited societies."@en . . . "I, P(ED0030/01/01), P(ED2.1.00/03.0101), P(LM2010004), S, V, Z(MZ0MOU2005)" . "Vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS jako sou\u010D\u00E1st algoritmu l\u00E9\u010Dby metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu"@cs . "Koc\u00E1kov\u00E1, Ilona" . . "22"^^ . "6" . . . "RIV/00209805:_____/11:#0000449!RIV14-MZ0-00209805" . . . "Vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS jako sou\u010D\u00E1st algoritmu l\u00E9\u010Dby metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu" . . "Knofl\u00ED\u010Dkov\u00E1, Dana" . . "240106" . . "Fabian, Pavel" . . . . "http://www.prolekare.cz/casopis-lekaru-ceskych-clanek/vysetreni-mutacniho-statutu-genu-kras-jako-soucast-algoritmu-lecby-metastatickeho-kolorektalniho-karcinomu-35498" . "[15BCC7E9C683]" . . "RIV/00209805:_____/11:#0000449" . "C\u00EDlen\u00E1 l\u00E9\u010Dba se st\u00E1v\u00E1 sou\u010D\u00E1st\u00ED standardn\u00EDch terapeutick\u00FDch postup\u016F zhoubn\u00FDch n\u00E1dor\u016F. V p\u0159\u00EDpad\u011B karcinomu tlust\u00E9ho st\u0159eva a kone\u010Dn\u00EDku je to nej\u010Dast\u011Bji terapie pomoc\u00ED monoklon\u00E1ln\u00EDch anti-EGFR protil\u00E1tek (cetuximab a panitumumab). Aktiva\u010Dn\u00ED somatick\u00E9 mutace v kodonech 12 a 13 exonu 2 genu KRAS jsou negativn\u00EDm prediktivn\u00EDm faktorem l\u00E9\u010Debn\u00E9 odpov\u011Bdi na anti-EGFR terapii u pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem. V \u010Cesk\u00E9 republice se prov\u00E1d\u00ED vy\u0161et\u0159en\u00ED genu KRAS v n\u011Bkolika referen\u010Dn\u00EDch laborato\u0159\u00EDch. V roce 2009 bylo v t\u011Bchto laborato\u0159\u00EDch provedeno 2580 vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS, z nich\u017E bylo 60,2 % p\u0159\u00EDpad\u016F nemutovan\u00FDch, tedy wild-type KRAS. Na p\u0159\u00EDkladu jedn\u00E9 laborato\u0159e je demonstrov\u00E1na logistika vy\u0161et\u0159ov\u00E1n\u00ED muta\u010Dn\u00EDho statutu genu KRAS. Stratifikace pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem zva\u017Eovan\u00FDch pro c\u00EDlenou anti-EGFR terapii na z\u00E1klad\u011B p\u0159\u00EDtomnosti mutac\u00ED v kodonech 12 a 13 genu KRAS je dnes standardn\u00EDm postupem. Laborato\u0159 prov\u00E1d\u011Bj\u00EDc\u00ED toto vy\u0161et\u0159en\u00ED by m\u011Bla postupovat v souladu s doporu\u010Den\u00EDmi odborn\u00FDch spole\u010Dnost\u00ED." . . "K-RAS; colorectal carcinoma; targeted therapy; anti-EGFR therapy; predictive molecular oncology; standardization of diagnostic procedure"@en . . . "KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma"@en . "CZ - \u010Cesk\u00E1 republika" . . . . "0008-7335" . "8"^^ . . "6"^^ . . "C\u00EDlen\u00E1 l\u00E9\u010Dba se st\u00E1v\u00E1 sou\u010D\u00E1st\u00ED standardn\u00EDch terapeutick\u00FDch postup\u016F zhoubn\u00FDch n\u00E1dor\u016F. V p\u0159\u00EDpad\u011B karcinomu tlust\u00E9ho st\u0159eva a kone\u010Dn\u00EDku je to nej\u010Dast\u011Bji terapie pomoc\u00ED monoklon\u00E1ln\u00EDch anti-EGFR protil\u00E1tek (cetuximab a panitumumab). Aktiva\u010Dn\u00ED somatick\u00E9 mutace v kodonech 12 a 13 exonu 2 genu KRAS jsou negativn\u00EDm prediktivn\u00EDm faktorem l\u00E9\u010Debn\u00E9 odpov\u011Bdi na anti-EGFR terapii u pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem. V \u010Cesk\u00E9 republice se prov\u00E1d\u00ED vy\u0161et\u0159en\u00ED genu KRAS v n\u011Bkolika referen\u010Dn\u00EDch laborato\u0159\u00EDch. V roce 2009 bylo v t\u011Bchto laborato\u0159\u00EDch provedeno 2580 vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS, z nich\u017E bylo 60,2 % p\u0159\u00EDpad\u016F nemutovan\u00FDch, tedy wild-type KRAS. Na p\u0159\u00EDkladu jedn\u00E9 laborato\u0159e je demonstrov\u00E1na logistika vy\u0161et\u0159ov\u00E1n\u00ED muta\u010Dn\u00EDho statutu genu KRAS. Stratifikace pacient\u016F s metastatick\u00FDm kolorekt\u00E1ln\u00EDm karcinomem zva\u017Eovan\u00FDch pro c\u00EDlenou anti-EGFR terapii na z\u00E1klad\u011B p\u0159\u00EDtomnosti mutac\u00ED v kodonech 12 a 13 genu KRAS je dnes standardn\u00EDm postupem. Laborato\u0159 prov\u00E1d\u011Bj\u00EDc\u00ED toto vy\u0161et\u0159en\u00ED by m\u011Bla postupovat v souladu s doporu\u010Den\u00EDmi odborn\u00FDch spole\u010Dnost\u00ED."@cs . "Vysko\u010Dilov\u00E1, Martina" . "150" . . . . "Nenutil, Rudolf" . "Vy\u0161et\u0159en\u00ED muta\u010Dn\u00EDho statutu genu KRAS jako sou\u010D\u00E1st algoritmu l\u00E9\u010Dby metastatick\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu"@cs .